Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP64: Utilising genomics to predict outcomes and delineate novel subgroups in inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: James Ashton
Created: Friday, 14 July 2023, 2:22 PM
DOP65: Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial
Year: 2024
Source: ECCO'24 Stockholm
Authors: Amiot, Aurelien
Created: Tuesday, 30 April 2024, 5:03 PM
DOP65: T-cell derived TGFβ1 remodels the rectum mesenchyme in Crohn’s Disease patients with perianal fistulizing disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Victoria Gudiño
Created: Friday, 14 July 2023, 2:22 PM
DOP66: Ileal resections from fibrotic-CD patients present microbiota dysbiosis, altered metabolomic profiles and metabolite-sensing GPCRs expression
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Cristina Bauset
Created: Friday, 14 July 2023, 2:22 PM
DOP66: INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s Disease and complex perianal fistulas
Year: 2024
Source: ECCO'24 Stockholm
Authors: Fathallah, Nadia
Created: Tuesday, 30 April 2024, 5:03 PM
DOP67: A transcriptional module associated with neutrophil degranulation is highly conserved across species and is a core molecular pathway of treatment resistance in ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Domenico Cozzetto
Created: Friday, 14 July 2023, 2:22 PM
DOP67: CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signaling pathway
Year: 2020
Source: ECCO'20 Vienna
Authors: Jieun Shin
Created: Tuesday, 23 June 2020, 5:40 PM
DOP67: MB310: From Clinical FMT to a Phase 1 Study with a Defined, Orally Administered Live Bacterial Therapeutic for Mild Moderate Ulcerative Colitis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Carter, Ron
Created: Tuesday, 30 April 2024, 5:03 PM
DOP68: Autophagy induction in the intestinal epithelium protects against inflammation-induced barrier loss in vivo.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kushal Saha
Created: Friday, 14 July 2023, 2:22 PM
DOP68: Natural history of isolated Crohn's Disease perianal fistula
Year: 2024
Source: ECCO'24 Stockholm
Authors: Wong, Serre-Yu
Created: Tuesday, 30 April 2024, 5:03 PM
DOP69: Glycans as an actor in the microbiome-immune response crosstalk.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Salomé Pinho
Created: Friday, 14 July 2023, 2:22 PM
DOP69: Longitudinal gut microbiome dynamics in relation to disease flares in Inflammatory Bowel Disease, pilot data from the IBD-Tracker study
Year: 2024
Source: ECCO'24 Stockholm
Authors: Gacesa, Ranko
Created: Tuesday, 30 April 2024, 5:03 PM
DOP69: Tofacitinib in Ulcerative Colitis: Early ‘real world’ experience from four United Kingdom tertiary centres
Year: 2020
Source: ECCO'20 Vienna
Authors: Desmond Chee
Created: Tuesday, 23 June 2020, 5:40 PM
DOP70: Crohn’s Disease Like Inflammation of The Pouch is a Distinct Type of Pouchitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Maia Kayal
Created: Friday, 14 July 2023, 2:22 PM
DOP70: High dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in Inflammatory Bowel Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Peter Hasselblatt
Created: Tuesday, 23 June 2020, 5:40 PM
DOP70: Prevalence and severity of bowel urgency in Crohn’s Disease: Results from the Communicating Needs and Features of IBD Experience (CONFIDE) Survey
Year: 2024
Source: ECCO'24 Stockholm
Authors: Dubinsky, Marla C
Created: Tuesday, 30 April 2024, 5:03 PM
DOP71: Effectiveness of dose escalation in Crohn’s Disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy - A multicenter international cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Uri Kopylov
Created: Tuesday, 23 June 2020, 5:40 PM
DOP71: Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
Year: 2024
Source: ECCO'24 Stockholm
Authors: Sands, Bruce E
Created: Tuesday, 30 April 2024, 5:03 PM
DOP71: Efficacy, safety, and tolerability of ustekinumab in pediatric patients with moderately to severely active Crohn’s Disease: Results from, UniStar, a phase 1 study
Year: 2020
Source: ECCO'20 Vienna
Authors: Joel Rosh
Created: Tuesday, 23 June 2020, 5:40 PM
DOP71: TREM1, OSM and a co-expressed transcriptional module are core components of the molecular resistome to anti-cytokine therapy in Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Aamir Saifuddin
Created: Friday, 14 July 2023, 2:22 PM